[en] OBJECTIVE: To assess the effect of adalimumab on work productivity and indirect costs in patients with Crohn's disease (CD) using a meta-analysis of clinical trials. METHODS: Study-level results were pooled from all clinical trials of adalimumab for moderate to severe CD in which work productivity outcomes were evaluated. Work Productivity and Activity Impairment Questionnaire outcomes (absenteeism, presenteeism and total work productivity impairment [TWPI]) were extracted from adalimumab trials. Meta-analyses were used to estimate pooled averages and 95% CIs of one-year accumulated reductions in work productivity impairment with adalimumab. Pooled averages were multiplied by the 2008 United States national average annual salary ($44,101) to estimate per-patient indirect cost savings during the year following adalimumab initiation. RESULTS: The four included trials (ACCESS, CARE, CHOICE and EXTEND) represented a total of 1202 employed adalimumab-treated patients at baseline. Each study followed patients for a minimum of 20 weeks. Pooled estimates (95% CIs) of one-year accumulated work productivity improvements were as follows: -9% (-10% to -7%) for absenteeism; -22% (-26% to -18%) for presenteeism; and -25% (-30% to -20%) for TWPI. Reductions in absenteeism and TWPI translated into per-patient indirect cost savings (95% CI) of $3,856 ($3,183 to $4,529) and $10,964 ($8,833 to $13,096), respectively. CONCLUSION: Adalimumab provided clinically meaningful improvements in work productivity among patients with moderate to severe CD, which may translate into substantial indirect cost savings from an employer's perspective.
Disciplines :
Gastroenterology & hepatology
Author, co-author :
Binion, David G
Louis, Edouard ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie
Oldenburg, Bas
Mulani, Parvez
Bensimon, Arielle G
Yang, Mei
Chao, Jingdong
Language :
English
Title :
Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease: a meta-analysis.
Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn's disease in adults. Am J Gastroenterol 2009;104:465-83.
Feagan BG, Bala M, Yan S, et al. Unemployment and disability in patients with moderately to severely active Crohn's disease. J Clin Gastroenterol 2005;39:390-5. (Pubitemid 40548076)
Stark R, König HH, Leidl R. Costs of inflammatory bowel disease in Germany. Pharmacoeconomics 2006;24:797-814. (Pubitemid 44232107)
Yu AP, Cabanilla LA, Wu EQ, et al. The costs of Crohn's disease in the United States and other Western countries: A systematic review. Curr Med Res Opin 2008;24:319-28. (Pubitemid 351294380)
Mesterton J, Jönsson L, Almer SH, et al. Resource use and societal costs for Crohn's disease in Sweden. Inflamm Bowel Dis 2009;15:1882-90.
Zisman TL, Cohen RD. Pharmacoeconomics and quality of life of current and emerging biologic therapy for inflammatory bowel disease. Curr Treat Options Gastroenterol 2007;10:185-94. (Pubitemid 46938928)
Feagan BG, Reilly MC, Gerlier L, et al. Clinical trial: The effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study. Aliment Pharmacol Ther 2010;31:1276-85.
Lichtiger S, Present D, Persson B, et al. T1062 improvement in work productivity with adalimumab in Crohn's disease patients who failed prior infliximab: An analysis of the CHOICE trial. Gastroenterology 2008;134:A475. (Abst)
Loftus E, Binion D, Panaccione R, et al. The ACCESS trial: Adalimumab improves work productivity in patients with Crohn's disease. Am J Gastroenterol 2008;103(Suppl 1):S382.
Louis E, Lofberg R, Reinisch W, et al. The CARE trial: Adalimumab improves work productivity and quality of life in patients with Crohn's disease (Abst P069). Presented at the Fourth Congress of the European Crohn's and Colitis Organisation. Hamburg, February 5 to 7, 2009.
Rutgeerts P, Binion D, Van Assche G, et al. Adalimumab improves work productivity in patients with moderate to severe Crohn's disease: The EXTEND trial (Abst P0333). Presented at Gastro 2009. London, November 21 to 25, 2009.
Reilly MC, Gerlier L, Brabant Y, et al. Validity, reliability, and responsiveness of the work productivity and activity impairment questionnaire in Crohn's disease. Clin Ther 2008;30:393-404. (Pubitemid 351474386)
Prasad M, Wahlqvist P, Shikiar R, et al. A review of self-report instruments measuring health-related work productivity: A patient-reported outcomes perspective. Pharmacoeconomics 2004;22:225-44. (Pubitemid 38393392)
Egger M, Davey Smith G, Altman DG. Systematic Reviews in Health Care: Meta-analysis in Context, 2nd edn. London: BMJ Publishing Group, 2001.
Reilly MC, Brown MCJ, Brabant Y, et al. Minimally important difference for WPAI:CD scores: Defining relevant impact on work productivity in active Crohn's disease (Abst 962). Presented at the American College of Gastroenterology Annual Scientific Meeting. Philadelphia, October 12 to 17, 2007.
US Bureau of Labor Statistics. National compensation survey: Occupational earnings in the United States, 2008. 〈www.bls.gov/ncs/ncswage2008. htm#Wage-Tables〉 (Accessed on June 7, 2010).
Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial. Gastroenterology 2007;132:52-65. (Pubitemid 46108762)
Loftus EV, Feagan BG, Colombel JF, et al. Effects of adalimumab maintenance therapy on health-related quality of life of patients with Crohn's disease: Patient-reported outcomes of the CHARM trial. Am J Gastroenterol 2008;103:3132-41.